FDA Approves Ozempic for Kidney and Heart Protection in Diabetic Patients

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's (NYSE:NVO) Ozempic for reducing the risk of kidney failure, disease progression, and death due to heart issues in diabetes patients with chronic kidney disease (CKD). This landmark approval makes Ozempic, chemically known as semaglutide, the first GLP-1 receptor agonist approved for type 2 diabetes patients with CKD.

Ozempic, already a blockbuster drug for diabetes, shares the same active ingredient as Novo’s obesity treatment, Wegovy. Its new indication builds on data from a late-stage trial showing a 24% reduction in the risk of death from CKD and major cardiac events. The FDA had previously approved Ozempic for lowering cardiovascular risks in adults with diabetes and heart disease.

Analysts highlight this approval as further proof of GLP-1 receptor agonists’ expanding therapeutic potential beyond type 2 diabetes and obesity. BMO Capital's Evan Seigerman called the decision part of a growing body of evidence supporting these drugs in broader applications.

Globally, CKD impacts about 40% of type 2 diabetes patients, with approximately 37 million U.S. adults affected. Last month, the European Medicines Agency approved adding kidney risk reduction to Ozempic's label.

Novo Nordisk is also exploring GLP-1 treatments for other conditions, including Alzheimer’s and non-alcoholic steatohepatitis (NASH). Last year, the FDA approved Wegovy to reduce stroke and heart attack risks in overweight or obese adults without diabetes.

Novo Nordisk’s continued innovation in GLP-1 therapies highlights its commitment to addressing complex health challenges.